ChemoCentryx

Biopharma’s 5 Biggest M&A Deals of 2022
BioSpace
Wed, 12/14/22 - 10:50 am
M&A
Amgen
Horizon Therapeutics
Pfizer
Biohaven
Global Blood Therapeutics
Bristol Myers Squibb
Turning Point Therapeutics
ChemoCentryx
SITC 2022 preview – cytokines and oral checkpoints
EP Vantage
Thu, 10/6/22 - 10:39 am
SITC
Incyte
ChemoCentryx
Amgen
cytokines
No big bang for biopharma buyouts
EP Vantage
Wed, 10/5/22 - 10:29 am
M&A
Pfizer
Global Blood Therapeutics
Amgen
ChemoCentryx
Novo Nordisk
Forma
Alcon
Aerie Pharmaceuticals
Gilead Sciences
MiroBio
Amgen, on an M&A spree, inks $3.7B ChemoCentryx buyout to boost inflammatory disease presence
Fierce Pharma
Thu, 08/4/22 - 12:10 pm
Amgen
M&A
patent cliff
ChemoCentryx
Big Pharma Is Going Holiday Shopping. Who's Next?
Motley Fool
Wed, 11/10/21 - 10:13 am
Big Pharma
M&A
ChemoCentryx
Epizyme
Magenta Therapeutics
3 Biotech Stocks That Could Rise 90% or More, According to Wall Street
Motley Fool
Sun, 10/17/21 - 10:57 pm
ChemoCentryx
Ocular Therapeutics
Axsome Therapeutics
Flash FDA approval sends ChemoCentryx spiralling upwards
Pharmaforum
Sun, 10/10/21 - 09:48 pm
ChemoCentryx
FDA
avacopan
Tavneos
ANCA-positive vasculitis
The big approvals still on the cards for 2021
EP Vantage
Thu, 06/17/21 - 11:00 am
FDA
drug approvals
Argenx
Novartis
AstraZeneca
Astellas
UCB Pharma
Ascendis Pharma
ChemoCentryx
Axsome Therapeutics
Adcomm splits slightly in favor of FDA approving ChemoCentryx’s rare disease drug
Endpoints
Thu, 05/6/21 - 11:06 pm
FDA
advisory panels
ChemoCentryx
avacopan
ANCA-positive vasculitis
Chemocentryx takes a leap of faith with avacopan
EP Vantage
Thu, 10/29/20 - 12:13 pm
ChemoCentryx
avacopan
clinical trials
hidradenitis suppurativa
ChemoCentryx Drug Hits Co-Primary Endpoints in Phase III Vasculitis Trial
BioSpace
Tue, 11/26/19 - 11:37 pm
ChemoCentryx
Vifor Fresenius Medical Care Renal Pharma
avacopan
ANCA-positive vasculitis
clinical trials
Pancreatic cancer combo sees high survival rates in ChemoCentryx PhIb data
Endpoints
Tue, 01/23/18 - 02:48 pm
pancreatic cancer
ChemoCentryx
CCX872
ChemoCentryx’s (CCXI) CCX168 Receives Orphan Drug Status
Bidness Etc.
Fri, 11/21/14 - 08:36 am
ChemoCentryx
CCX168
orphan drugs
aHUS
Five Small Biotech Stocks Analysts Think Will Triple
Forbes
Thu, 05/1/14 - 07:23 am
Arrowhead Research
ChemoCentryx
Ziopharm
TherapeuticsMD
Dynavax
3 Horrendous Health-Care Stocks This Week
Motley Fool
Sat, 09/14/13 - 11:01 am
Neurocrine Biosciences
ChemoCentryx
GSK
Avanir
Neurocrine And ChemoCentryx: Phase II Data Disappoints
Seeking Alpha
Wed, 09/11/13 - 11:25 am
Neurocrine
ChemoCentryx
CCX140
NBI-98854
tardive dyskinesia
diabetic nephropathy
ChemoCentryx Falls on Weak Diabetic Nephropathy Drug Data
TheStreet.com
Tue, 09/10/13 - 11:37 am
ChemoCentryx
diabetic nephropathy
CCX140
The Impact of a Failed Crohn's Disease Trial Study
Motley Fool
Fri, 08/30/13 - 10:36 am
Crohn's Disease
Vercirnon
ChemoCentryx
GSK
3 Horrendous Health-Care Stocks This Week
Motley Fool
Sat, 08/24/13 - 11:48 am
ChemoCentryx
Aglos Pharmaceuticals
Prosensa
GSK's Crohn's disease treatment fails in Phase III trial
Reuters
Fri, 08/23/13 - 11:11 am
GSK
Crohn's Disease
ChemoCentryx
Vercirnon

Pages